Keyword: Brigham and Women's Hospital
Alexion bought Syntimmune last year based on data showing that SYNT001 could lower both IgG levels and IgG circulating immune complexes.
A Brigham and Women's team found a microRNA in the microbiome that increases when MS peaks. Giving it back to mice as a treatment relieved symptoms.
The partners will work out of a joint lab at Brigham and Women's Hospital in Boston that will receive more than $30 million over the next five years.
A phase 1 clinical trial of Ziopharm's IL-12 gene therapy and a production "switch" shows promise in recurrent glioblastoma.
The FDA aims to test the capabilities of real-world evidence by trying to predict the results of randomized, controlled trials before completion.
MIT and Novo Nordisk scientists have come up with an oral insulin delivery system that shows promise in lowering glucose levels in animal studies.
Modifying tumor cells instead of immune cells from patients is showing promising results in animal models of breast and brain cancer.
Last week’s biotech discoveries include a gut-coating pill that lowers glucose and prostate-tumor test to predict a good response to immunotherapy.
A PureTech startup is developing an immune-responsive hydrogel that releases a corticosteroid into arthritic joints based on their level of inflammation.
The hospital network achieved the jump in scale by turning to outside backers including Eli Lilly, which collectively pumped $66 million into the fund.